13 Treatment groups Experimental Treatment Placebo Group Part A Randomized 1:1 Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part C Sema and SC moderate dose trevo Randomized 1:2:2 Part C Sema and SC low dose trevo Randomized 1:2:2 Part C Sema and SC placebo Randomized 1:2:2 Part A Randomized 1:1 Find a Clinic Near You Who Is Running the Clinical Trial
PlexusDx recommends working closely with a healthcare provider throughout your treatment to monitor your response and adjust dosing cautiously
The reconstituted peptide solution, however, follows the peptide's own storage rules see Peptide Storage Guide
The benefits of GLP-1s are real for some women and specific clinical conditions, but they do not replace a comprehensive view of menopausal health
.png)
